307 related articles for article (PubMed ID: 24824093)
1. Lenalidomide desensitization for delayed hypersensitivity reactions in 5 patients with multiple myeloma.
Lee MJ; Wickner P; Fanning L; Schlossman R; Richardson P; Laubach J; Castells M
Br J Haematol; 2014 Oct; 167(1):127-31. PubMed ID: 24824093
[No Abstract] [Full Text] [Related]
2. Desensitization to lenalidomide in a patient with relapsed multiple myeloma.
Seki JT; Banglawala S; Lentz EM; Reece DE
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):162-5. PubMed ID: 23103087
[No Abstract] [Full Text] [Related]
3. Successful desensitization to pomalidomide in a patient with POEMS syndrome with delayed-type hypersensitivity to immunomodulatory imid drugs.
Grandoni F; Stalder G; Borgeat Kaeser A; Ribi C; Cairoli A; Blum S
Leuk Lymphoma; 2019 Dec; 60(12):3087-3089. PubMed ID: 31161829
[No Abstract] [Full Text] [Related]
4. Desensitization to thalidomide in a patient with multiple myeloma.
Nucera E; Schiavino D; Hohaus S; Leone G; Buonomo A; Lombardo C; Patriarca G
Clin Lymphoma Myeloma; 2008 Jun; 8(3):176-8. PubMed ID: 18650182
[TBL] [Abstract][Full Text] [Related]
5. Successful desensitization in a patient with lenalidomide hypersensitivity.
Phillips J; Kujawa J; Davis-Lorton M; Hindenburg A
Am J Hematol; 2007 Nov; 82(11):1030. PubMed ID: 17617781
[No Abstract] [Full Text] [Related]
6. [Desensitization to lenalidomide].
Cañamares Orbis I; García Muñoz C; Cortijo Cascajares S; Méndez Esteban ME
Farm Hosp; 2012; 36(6):542-3. PubMed ID: 23461448
[No Abstract] [Full Text] [Related]
7. Slow lenalidomide desensitization protocol for patients with multiple myeloma: case series from a single center.
Yau P; Jimenez-Zepeda VH; Bailey K; Duggan P; Tay J; Bahlis NJ; Neri P; McCulloch S
Leuk Lymphoma; 2019 Dec; 60(13):3199-3203. PubMed ID: 31190585
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide-induced cytokine release syndrome in a patient with multiple myeloma.
Nakamura N; Kanemura N; Shibata Y; Matsumoto T; Mabuchi R; Nakamura H; Kitagawa J; Goto N; Hara T; Tsurumi H; Moriwaki H
Leuk Lymphoma; 2014 Jul; 55(7):1691-3. PubMed ID: 24138307
[No Abstract] [Full Text] [Related]
9. Acute lymphoblastic leukemia developing during maintenance therapy with lenalidomide in a patient with multiple myeloma.
García-Muñoz R; Robles-de-Castro D; Muñoz-Rodríguez A; Rabasa P
Leuk Lymphoma; 2013 Dec; 54(12):2753-5. PubMed ID: 23488662
[No Abstract] [Full Text] [Related]
10. Classical hodgkin lymphoma as de novo B-cell malignancy after treatment of multiple myeloma in the pre-lenalidomide era.
Zago M; Adam P; Goldschmidt H; Fend F; Kanz L; Weisel K
Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):e7-e11. PubMed ID: 24169269
[No Abstract] [Full Text] [Related]
11. Successful desensitization procedure to lenalidomide in a patient with delayed hypersensitivity confirmed with a positive LTT.
Lazzarato I; Gonzalez-Muñoz M; Heredia R; Castellar PharmG FR; López de la Guía A; Cabañas R; Fiandor A; Dominguez-Ortega J
Eur Ann Allergy Clin Immunol; 2020 Sep; 52(5):235-237. PubMed ID: 32374557
[No Abstract] [Full Text] [Related]
12. Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer.
Bennett CL; Angelotta C; Yarnold PR; Evens AM; Zonder JA; Raisch DW; Richardson P
JAMA; 2006 Dec; 296(21):2558-60. PubMed ID: 17148721
[No Abstract] [Full Text] [Related]
13. Novel immunomodulatory compounds in multiple myeloma.
Saini N; Mahindra A
Expert Opin Investig Drugs; 2013 Feb; 22(2):207-15. PubMed ID: 23265189
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide: A Review in Newly Diagnosed Multiple Myeloma as Maintenance Therapy After ASCT.
Syed YY
Drugs; 2017 Sep; 77(13):1473-1480. PubMed ID: 28791622
[TBL] [Abstract][Full Text] [Related]
15. Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study.
Wolschke C; Stübig T; Hegenbart U; Schönland S; Heinzelmann M; Hildebrandt Y; Ayuk F; Atanackovic D; Dreger P; Zander A; Kröger N
Exp Hematol; 2013 Feb; 41(2):134-142.e3. PubMed ID: 23085463
[TBL] [Abstract][Full Text] [Related]
16. Long-term response to lenalidomide in patients with newly diagnosed multiple myeloma.
Kourelis TV; Kumar SK; Srivastava G; Gertz MA; Lacy MQ; Buadi FK; Kyle RA; Dispenzieri A
Leukemia; 2014 Feb; 28(2):455-7. PubMed ID: 24150218
[No Abstract] [Full Text] [Related]
17. 'Real-world' Australian experience of pomalidomide for relapsed and refractory myeloma.
Scott A; Weber N; Tiley C; Taylor K; Taper J; Harrison S; Chan KL; Stark R; Lee C; Morris K; Ho PJ; Dodds A; Ramanathan S; Ramakrishna R; Watson AM; Auguston B; Kwok F; Quach H; Warburton P; Rowlings P; Mollee P
Leuk Lymphoma; 2018 Jun; 59(6):1514-1516. PubMed ID: 29022836
[No Abstract] [Full Text] [Related]
18. Lenalidomide in the treatment of multiple myeloma: a review.
Armoiry X; Aulagner G; Facon T
J Clin Pharm Ther; 2008 Jun; 33(3):219-26. PubMed ID: 18452408
[TBL] [Abstract][Full Text] [Related]
19. Outcomes and management of lenalidomide-associated rash in patients with multiple myeloma.
Barley K; He W; Agarwal S; Jagannath S; Chari A
Leuk Lymphoma; 2016 Nov; 57(11):2510-5. PubMed ID: 26943456
[TBL] [Abstract][Full Text] [Related]
20. Pomalidomide-Induced Pulmonary Toxicity in Multiple Myeloma.
Modi D; Mamdani H; Vettese T
Am J Med Sci; 2015 Sep; 350(3):241-2. PubMed ID: 26200951
[No Abstract] [Full Text] [Related]
[Next] [New Search]
